Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 199-206

  Cavaletti, G ^a   Bogliun, G ^a   Crespi, V ^a   Marzorati, L ^a   Zincone, A ^a   Marzola, M ^a   Rota, S ^a   Galli, A ^a   Tredici, P ^a   Tredici, G ^a  

^a Department of Neurology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; OTOTOXICITY; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031015260     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.199     Document Type: Article

References (30)

1. Neijt JP, ten Bokkel Huinink WW, van den Burg ME, et al: Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma. Lancet 2:594-600, 1984
2. Williams CJ, Mead GM, Macbeth FR, et al: Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: Mature results of a randomized trial. J Clin Oncol 3:1455-1462, 1985
3. Omura GA, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: A Gynecologic Oncology Group study. Cancer 57:1725-1730, 1986
4. Thigpen JT, Blessing JA, Vance RB, et al: Chemotherapy in ovarian carcinoma: Present role and future prospects. Semin Oncol 16:58-65, 1989 (suppl 6)
5. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 303:884-893, 1991
6. Hansen HH, Eisenhauer EA, Hansen M, et al: New cytostatic drugs in ovarian cancer. Ann Oncol 4:S63-S70, 1993 (suppl 4)
7. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
8. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
9. Cersosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev 16:195-211, 1989
10. Rowinsky EK, Onetto N, Canetta RM, et al: Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646-662, 1992
11. Mollman JE: Cisplatin neurotoxicity. N Engl J Med 322:126-127, 1990
12. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
13. Cavaletti G, Bogliun G, Marzorati L, et al: Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin. Cancer 75:1141-1150, 1995
14. Chaudry V, Rowinsky EK, Sartorius SE, et al: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 35:304-311, 1994
15. Dyck PJ, Karnes JL, Daube J, et al: Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 108:861-880, 1985
16. Cavaletti G, Bogliun G, Marzorati L, et al: The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. J Neurol 238:371-374, 1991
17. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
18. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
19. Thompson SW, Davis LE, Kornfeld M, et al: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269-1275, 1984
20. Daugaard GK, Petrera J, Trojaborg W: Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand 76:86-93, 1987
21. Cavaletti G, Marzorati L, Bogliun G, et al: Cisplatin-induced peripheral neurotoxicity is dependent on total- and single-dose intensity. Cancer 69:203-207, 1992
22. Cavaletti G, Tredici G, Marmiroli P, et al: Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (CDDP) administration in rats. Acta Neuropathol 84:364-371, 1992
23. Hamers FPT, Pette C, Bravenboer B, et al: Cisplatin-induced neuropathy in mature rats: effect of the melanocortin-derived peptide ORG 2766. Cancer Chemother Pharmacol 32:162-166, 1993
24. Lipton RB, Apfel SC, Dutcher JP, et al: Taxol produces a predominantly sensory neuropathy. Neurology 39:368-373, 1989
25. Sahenk Z, Barohn R, New P, et al: Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51:726-729, 1994
26. Rowinsky EK, Eisenhauer EA, Chaudry V, et al: Clinical toxicities encountered with paclitaxel (TAXOL). Semin Oncol 20:1-15, 1993 (suppl 3)
27. Cavaletti G, Tredici G, Braga M, et al: Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of Taxol. Exp Neurol 133:64-72, 1995
28. Cavaletti G, Cavalletti E, Montaguti P, et al: Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicol (in press)
29. Marzorati L, Bogliun G, Cavaletti G: Clinical and neurophysiologic evaluation of the effect of cisplatin administration on the motor nerves. Int J Oncol 2:81-84, 1993
30. Vermorken JB, Kapteyn TS, Hart AAM, et al: Ototoxicity of CDDP: Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19:53-58, 1983